Share Your Voice During National Diabetes Awareness Month
T1D Exchange Quality Improvement Collaborative (QIC) Reaches 25 Diabetes Centers Participating Nationwide
QIC Clinics Collaborate to Share Data and Improve Outcomes for People with Type 1 Diabetes T1D Exchange, a nonprofit organization…
New Data Reveals the Social Inequities Underlying DKA Risk in Type 1 Diabetes and COVID-19
Dr. Osagie Ebekozien (Vice President of Quality Improvement & Population Health, T1D Exchange) presented alarming evidence showing a strong association…
Lilly and Dexcom team up
Lilly and Dexcom team up on new program to help improve diabetes management Eli Lilly and Company (NYSE: LLY) and DexCom, Inc. (NASDAQ:…
Beyond Type 1 Launches GetInsulin.org
This morning, Beyond Type 1 announced the launch of GetInsulin.org. This new, critical tool connects people in the United States…
Boston 25 News – Boston-Based Study Blazing Trail on COVID-19 Connection to Diabetes
The ongoing outbreak of the novel respiratory disease COVID-19 has become a significant threat to global health and individuals with pre-existing medical conditions. To gain a deeper understanding of how the coronavirus is affecting people with type 1 diabetes, T1D Exchange is leading a first-of-its-kind COVID-19 research surveillance study in partnership with more than 50 …
Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar
Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …
Continue reading “Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar”
Tandem CCO Brian Hansen Discusses FDA Approval for Control IQ Algorithm with t:slim X2
Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.
